Fred Hutch Cancer Center | Strategic Alliance Partners
Latest from Fred Hutch Cancer Center
Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.
Assessing HER2 Expression in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Biomarker Testing in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.
Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.
Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.
Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.
Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.
Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.
First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.
Novel Treatment Strategies in Muscle Invasive Bladder Cancer
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.
Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.
Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.
Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.
Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.
Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.
Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
Overview of Practice Patterns in Urothelial Carcinoma
ByShilpa Gupta, MD, Cleveland Clinic,Andrea B. Apolo, MD, National Cancer Institute,Petros Grivas MD, PhD,Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
